Previous 10 | Next 10 |
CV Sciences, Inc. (OTCQB: CVSI) sales fell in the quarter as demand for hemp-derived products continues to fade. The hemp operator announced its financial results for the quarter ending June 30, 2022. CV Sciences delivered approximately $4.1 million in total revenue during the...
CV Sciences press release ( OTCQB:CVSI ): Q2 Non-GAAP EPS of -$0.02 beats by $0.01 . Revenue of $4.1M (-20.1% Y/Y) misses by $0.78M . Gross margin of 30.7% for second quarter of 2022, compared to 44.7% for the second quarter of 2021; Total cash balance of $1.1 ...
CV Sciences, Inc. Reports Second Quarter 2022 Financial Results PR Newswire SAN DIEGO , Aug. 15, 2022 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing ...
CV Sciences, Inc. (CVSI) Q1 2022 Results Conference Call May 16, 2022 10:00 AM ET Company Participants Joseph Dowling - CEO Joerg Grasser - CFO Conference Call Participants Scott Fortune - ROTH Capital Presentation Operator Greetings. Welcome to the CV Sciences First Quarter 2022 Conference C...
CV Sciences press release (OTCQB:CVSI): Q1 GAAP EPS of -$0.02 beats by $0.01. Revenue of $4.45M (-8.1% Y/Y) misses by $0.39M. “First quarter results met our expectations and we are encouraged by improvements in the retail channel including an increase in units shipped on a year over ye...
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced it...
CV Sciences (OTCQB:CVSI) is scheduled to announce Q1 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$0.03 (-50.0% Y/Y) and the consensus Revenue Estimate is $4.84M (+0.8% Y/Y). Over the last 2 years, CVSI has beaten EPS estimates 25% of the time and h...
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today anno...
CV Sciences press release (OTCQB:CVSI): FY Non-GAAP EPS of -$0.10. Revenue of $20.05M (+82.3% Y/Y). For further details see: CV Sciences Non-GAAP EPS of -$0.10, revenue of $20.05M
SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced ...
News, Short Squeeze, Breakout and More Instantly...
CV Sciences, Inc. Reports First Quarter 2024 Financial Results PR Newswire SAN DIEGO , May 14, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ex...
CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS, A FLEXIBLE, LOW-MOQ, NUTRACEUTICAL MANUFACTURER PR Newswire SAN DIEGO , May 13, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer we...
CV Sciences, Inc. To Announce First Quarter 2024 Results On May 14, 2024 PR Newswire SAN DIEGO , May 8, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company special...